We thank Drs J. Finsterer and S. Zarrouk-Mahjoub [1] for their comments regarding our report [2] on the beneficial effects of low dose clozapine for management of psychotic symptoms in a patient with neurogenic ataxia-retinitis pigmentosa (NARP mutation, m.8993T N C, maternally inherited from asymptomatic carrier mother). We agree that clozapine has many side effects, some of them being potentially lethal. Yet, 70% of patients on clozapine reportedly remained on the drug for a long period [3] and its mortality was reduced compared to that of other antipsychotics [4] . Indeed, because side effects usually occur at onset of treatment, careful monitoring allowed to prevent complications and its efficacy exempted from giving other antipsychotic medication and decreased suicide rate.
It is worth noting also that our patient neither experienced adverse haematological nor cardiac effects of clozapine. In France, monitoring blood count is mandatory in patients given clozapine (weekly for 18 weeks then monthly) [5] . The treatment is suspended if neutrophil count falls below 1500/mm 3 . Similarly, side cardiac effects are below 1% and their early detection by systematic EEG and ultrasounds allows to prevent heart complications. Using low dose Clozapine also reduces the occurrence of complications [6] . While low doses were well tolerated in our patient (37.5 mg/25 mg per day alternatively), higher doses triggered myoclonus and falls. On the contrary, extrapyramidal symptoms notably improved upon introduction of clozapine but remained clinically significant. This is probably due to the long lasting effect of the previously administered antipsychotics (risperidone, cyamemazine and aripiprazole). Clozapine metabolites may also have a neuroprotective effect on dopaminergic neurons [7] , as mentioned by our colleagues. While Clozapine had an overall beneficial effect, additional cases and long term follow-up are needed to consider clozapine as a first line treatment for psychotic symptoms in NARP syndrome.
